|Day Low/High||20.15 / 21.12|
|52 Wk Low/High||0.44 / 2.03|
X213 shown to be safe and effective, demonstrating complete suppression of lactation in study participants
Unmet medical needs in parathyroid hormone-related hypercalcemia contribute to potential partnering value of overall portfolio
Oral and Poster Presentations to Highlight Preclinical and Clinical Program Advances for Hypoglycemia and Hypercalcemia
Company extinguishes Hercules term loan; repayment further reduces operating expenses and strengthens XOMA's balance sheet, reflecting its new business strategy
Company outlines new strategic imperatives and value drivers
Congenital Hyperinsulinism Phase 2 study completed and multi-dose study protocol approved in the United Kingdom; Company initiates multi-dose study in hypoglycemic Post-Bariatric Surgery patients
In recent trading, shares of XOMA Corp have crossed above the average analyst 12-month target price of $1.09, changing hands for $6.24/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Company Reached Agreement with MHRA on General Trial Design for Multi-dose Testing in Children 2 Years and Older in the United Kingdom
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.